Bridging biology, technology, and clinical application
Biomarkers are rapidly transforming the future of medicine — from diagnostics to personalized therapies. As omics technologies generate vast and complex datasets, the challenge becomes how to meaningfully integrate this information into drug discovery workflows.
Join us to explore how Ardigen is advancing biomarker discovery through omic data integration strategies. This webinar, led by Krzysztof Kolmus, PhD, and Magdalena Budzińska-Zaniewska, PhD, will show how combining diverse data types — genomics, transcriptomics, proteomics, lipidomics, and metabolomics — with advanced analytics helps uncover powerful predictive and prognostic biomarkers.
The speakers will also present how synthetic lethality approaches can drive novel biomarker discovery by integrating multi-omics data to advance targeted cancer therapies and improve patient stratification.
What you’ll learn:
- Why biomarkers are critical to modern drug development and clinical practice
- How to leverage omics data integration across multiple stages of drug screening
- Key differences and use cases for univariate vs multivariate analyses
- Real-world case studies highlighting biomarker identification and validation
- How synthetic lethality can be exploited to discover predictive biomarkers for targeted therapies
- How Ardigen’s proprietary biomarkers solutions deliver deep biological insights
- What’s next: multi-modal data fusion and causal modeling in precision medicine
Who should attend
This webinar is ideal for:
- Bioinformaticians & Computational Biologists
- Translational Scientists & Clinical Researchers
- Pharmaceutical R&D Teams
- Biotech Innovators focused on precision medicine
- Anyone interested in biomarker strategies
Meet our speakers:

Krzysztof Kolmus, PhD
Krzysztof is a lead bioinformatician with a deep focus on biomarker discovery and target identification using omic datasets. With over a decade of experience in both academia and industry, he brings a translational mindset to uncovering clinically related insight from complex datasets. Holding a PhD in biotechnology, Krzysztof has contributed to numerous high-impact biomedical projects. He’s passionate about turning data into discoveries that can impact patient wellbeing. Join Krzysztof to explore how Ardigen proprietary platforms shape the future of biomarker science.

Magdalena Budzińska-Zaniewska, PhD
Magdalena is a lead bioinformatician with expertise in developing targeted therapies and mRNA vaccines. Her previous work focused on computational approaches that leverage multi-omics data to identify clinically relevant synthetic lethal interactions for cancer therapy. She bridges biomarker discovery and therapeutic implementation, helping to translate biomarkers into effective, targeted treatments through integrated computational and clinical validation.
Decode the Omics. Unlock the Cure.
Reserve your spot
Spots are limited — sign up now to secure your place and gain access to the latest insights at the intersection of biology, data science, and clinical application.